-
公开(公告)号:NO20012339L
公开(公告)日:2001-05-11
申请号:NO20012339
申请日:2001-05-11
Applicant: DUPHAR INT RES
Inventor: TOOROP GERRIT P , FEENSTRA ROELOF WILLEM , MOS JOHANNES , LONG STEPHEN KENNETH , VISSER GERBEN M , KRUSE CORNELIS GERRIT
IPC: A61K31/40 , A61K31/4164 , A61K31/42 , A61K31/425 , A61K31/4439 , A61K31/496 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D209/34 , C07D235/26 , C07D263/58 , C07D277/68 , C07D401/04 , C07D413/04 , C07D417/04
Abstract: The invention relates to a group of novel piperazine and piperidine derivatives of formula (I), wherein: S1 is hydrogen, halogen, alkyl (1-3C), CN, CF3, OCF3, SCF3, alkoxy (1-3C), amino or mono- or dialkyl (1-3C) substituted amino, or hydroxy; X represents NR3, S, CH2, O, SO or SO2, wherein R3 is H or alkyl (1-3C); . . . Z represents =C or -N; -R1 independently represent H or alkyl (1-3C), or R1 and R2 together can form a bridge 2 or 3 C-atoms; R4 is hydrogen or alkyl (1-3C); Q is methyl, ethyl, ethyl substituted with one or more fluorine atoms, cyclopropyl-methyl, optionally substituted with one or more fluorine atoms, and salts and prodrugs thereof. It has been found that these compounds have both partial dopamine D2-receptor agonism and partial serotonin 5-HT1A-receptor agonism mediated activities.
-
公开(公告)号:NO20012339A
公开(公告)日:2001-05-11
申请号:NO20012339
申请日:2001-05-11
Applicant: DUPHAR INT RES
Inventor: TOOROP GERRIT P , FEENSTRA ROELOF WILLEM , MOS JOHANNES , LONG STEPHEN KENNETH , VISSER GERBEN M , KRUSE CORNELIS GERRIT
IPC: A61K31/40 , A61K31/4164 , A61K31/42 , A61K31/425 , A61K31/4439 , A61K31/496 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D209/34 , C07D235/26 , C07D263/58 , C07D277/68 , C07D401/04 , C07D413/04 , C07D417/04
CPC classification number: C07D263/58 , C07D209/34 , C07D235/26 , C07D277/68 , C07D401/04 , C07D413/04 , C07D417/04 , Y02P20/55
-
13.
公开(公告)号:CA2270777C
公开(公告)日:2008-04-22
申请号:CA2270777
申请日:1998-09-07
Applicant: DUPHAR INT RES
Inventor: REINDERS JAN H , RONKEN ERIC , TULP MARTINUS T M , JANSEN JOHANNES W C M , VISSER GERBEN M , TOOROP GERRIT P , DEN HARTOG JACOBUS A J
IPC: C07D239/94 , A61K31/4375 , A61K31/47 , A61K31/4709 , A61K31/517 , A61K31/519 , A61K31/5377 , A61P25/00 , A61P25/20 , A61P25/22 , A61P25/24 , A61P43/00 , C07D215/42 , C07D401/04 , C07D401/12 , C07D413/12 , C07D471/04 , C07D487/04
Abstract: The invention relates to novel quinoline and quinazoline derivatives having corticotropin releasing factor (CRF) antagonist activity. It has been found that compounds having formula (I) wherein A is CH or N, ri ng Q is phenyl, pyridyl, pyrimidinyl or pyridazinyl, optionally substituted with one or two groups R4; ring Y is phenyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R1 and R2 are optionally branched C1-6-alkyl, C3-6-alkenyl, C3-46-alkynyl, C3-6-cycloalkyl - C1-4-alkyl, phenyl-C1-4-alkyl, 5- or 6-membered saturated or unsaturated heterocyclyl-C1-4-alkyl, which groups R1 and R2 can be substituted with OH, C1-3-alkoxy, C1-3-alkoxycarbonyl, optionally mono- or di-(C1-3-alkyl)substituted amino, halogen or cyano; R3 is H, C1-3- alkyl optionally substituted with one or more fluorine atoms, or R3 is halogen, methoxy or ethoxy; R4 is C1-3-alkyl optionally substituted with one or more fluorine atoms, or R4 is halogen, methoxy, ethoxy, amino, mono- or di-substituted amino, or cyano; R5 is halogen, optionally branched C1-6-alkyl, C3-6-alkenyl, C3-6-alkynyl, C3-6-cycloalkyl-C1-4-alkyl, O-(C1-6-alkyl), S-(C1-6-alkyl), SO 2- (C1-6-alkyl), hydroxy, cyano, nitro, trifluoromethyl, SO2NH2, SO2N(mono- or di-C1-4-alkyl), formyl, CO-(C1-6-alkyl), COOH, COO-(C1 -6- alkyl), CONH2, CON(mono- or di-C1-4-alkyl),amino, N(mono or di-C1-4-alkyl), NHCO(C1-46-alkyl), NHSO2-(C1-6-alkyl), which groups R5 can be identical or different; and n has the value 0 to 4; with the proviso that the group NR1R2 is not diethylamino, ethyl,n-propylamino or ethyl,n-butylamino, if A is CH, Q is unsubstituted phenyl, R3 is methyl, and substituent Y with the group(s) R 5 is 2,4,6-trimethylphenyl, and salts thereof have good CRF antagonist activity.
-
14.
公开(公告)号:SK285648B6
公开(公告)日:2007-05-03
申请号:SK6492001
申请日:1999-11-10
Applicant: DUPHAR INT RES
Inventor: FEENSTRA ROELOF W , VAN DER HEIJDEN JOHANNES A M , MOS JOHANNES , LONG STEPHEN K , VISSER GERBEN M , KRUSE CORNELIS G , VAN SCHARRENBURG GUSTAAF J M T , TOOROP GERRIT P , TOOROP ANNE G
IPC: C07D263/00 , A61K31/00 , A61K31/40 , A61K31/4164 , A61K31/42 , A61K31/425 , A61K31/4439 , A61K31/496 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D209/00 , C07D209/34 , C07D235/00 , C07D235/26 , C07D263/58 , C07D277/00 , C07D277/68 , C07D401/00 , C07D401/04 , C07D413/00 , C07D413/04 , C07D417/00 , C07D417/04
Abstract: It is disclosed a group of novel piperazine and piperidine derivatives of formula (I), wherein: S1 is hydrogen, halogen, alkyl (1-3C), CN, CF3, OCF3, SCF3, alkoxy (1-3C), amino or mono- or dialkyl (1-3C) substituted amino, or hydroxy; X represents NR3, S, CH2, O, SO or SO2, wherein R3 is H or alkyl (1-3C); .Z represents =C or -N; - R1 and R2 independently represent H or alkyl (1-3C), or R1 and R2 together can form a bridge of 2 or 3 C-atoms; R4 is hydrogen or alkyl (1-3C); Q is methyl, ethyl, ethyl substituted with one or more fluorine atoms, cyclopropyl - methyl, optionally substituted with one or more fluorine atoms, and salts thereof. These compounds have both partial dopamine D2-receptor agonism and partial serotonin 5-HT1A-receptor agonism mediated activities.
-
公开(公告)号:PL193685B1
公开(公告)日:2007-03-30
申请号:PL34763599
申请日:1999-11-10
Applicant: DUPHAR INT RES
Inventor: FEENSTRA ROELOF W , VAN DER HEIJDEN JOHANNES A M , MOS JOHANNES , LONG STEPHEN K , VISSER GERBEN M , KRUSE CORNELIS G , VAN SCHARRENBURG GUSTAAF J M , TOOROP GERRIT P
IPC: C07D413/04 , A61K31/40 , A61K31/4164 , A61K31/42 , A61K31/425 , A61K31/4439 , A61K31/496 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D209/34 , C07D235/26 , C07D263/58 , C07D277/68 , C07D401/04 , C07D417/04
Abstract: The invention relates to a group of novel piperazine and piperidine derivatives of formula (I), wherein: S1 is hydrogen, halogen, alkyl (1-3C), CN, CF3, OCF3, SCF3, alkoxy (1-3C), amino or mono- or dialkyl (1-3C) substituted amino, or hydroxy; X represents NR3, S, CH2, O, SO or SO2, wherein R3 is H or alkyl (1-3C); . . . Z represents =C or -N; -R1 independently represent H or alkyl (1-3C), or R1 and R2 together can form a bridge 2 or 3 C-atoms; R4 is hydrogen or alkyl (1-3C); Q is methyl, ethyl, ethyl substituted with one or more fluorine atoms, cyclopropyl-methyl, optionally substituted with one or more fluorine atoms, and salts and prodrugs thereof. It has been found that these compounds have both partial dopamine D2-receptor agonism and partial serotonin 5-HT1A-receptor agonism mediated activities.
-
公开(公告)号:AT348812T
公开(公告)日:2007-01-15
申请号:AT98950008
申请日:1998-09-07
Applicant: DUPHAR INT RES
Inventor: DEN HARTOG JACOBUS A J , VISSER GERBEN M , TOOROP GERRIT P , JANSEN JOHANNES W C M , RONKEN ERIC , TULP MARTINUS T M , REINDERS JAN H
IPC: A61K31/4375 , A61K31/47 , A61K31/4709 , A61K31/517 , A61K31/519 , A61P25/00 , A61P25/20 , A61P25/22 , A61P25/24 , A61P43/00 , C07D215/42 , C07D239/94 , C07D401/04 , C07D401/12 , C07D471/04 , C07D487/04
Abstract: The present invention relates to novel compounds, to a method for the preparation of these novel compounds, to pharmaceutical compositions containing one or more of these compounds as an active component and to methods of using these in the treatment of stress-related disorders.
-
公开(公告)号:SI1131308T1
公开(公告)日:2004-10-31
申请号:SI9930574
申请日:1999-11-10
Applicant: DUPHAR INT RES
Inventor: TOOROP GERRIT P , FEENSTRA ROELOF W , VAN DER HEIJDEN JOHANNES A M , MOS JOHANNES , LONG STEPHEN K , VISSER GERBEN M , KRUSE CORNELIS G , VAN SCHARRENBURG GUSTAAF J M , TOOROP ANNE G HF
IPC: A61K31/40 , A61K31/4164 , A61K31/42 , A61K31/425 , A61K31/4439 , A61K31/496 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D209/34 , C07D235/26 , C07D263/58 , C07D277/68 , C07D401/04 , C07D413/04 , C07D417/04
Abstract: The invention relates to a group of novel piperazine and piperidine derivatives of formula (I), wherein: S1 is hydrogen, halogen, alkyl (1-3C), CN, CF3, OCF3, SCF3, alkoxy (1-3C), amino or mono- or dialkyl (1-3C) substituted amino, or hydroxy; X represents NR3, S, CH2, O, SO or SO2, wherein R3 is H or alkyl (1-3C); . . . Z represents =C or -N; -R1 independently represent H or alkyl (1-3C), or R1 and R2 together can form a bridge 2 or 3 C-atoms; R4 is hydrogen or alkyl (1-3C); Q is methyl, ethyl, ethyl substituted with one or more fluorine atoms, cyclopropyl-methyl, optionally substituted with one or more fluorine atoms, and salts and prodrugs thereof. It has been found that these compounds have both partial dopamine D2-receptor agonism and partial serotonin 5-HT1A-receptor agonism mediated activities.
-
公开(公告)号:DK1131308T3
公开(公告)日:2004-06-28
申请号:DK99955980
申请日:1999-11-10
Applicant: DUPHAR INT RES
Inventor: FEENSTRA ROELOF W , VAN DER HEIJDEN JOHANNES A M , MOS JOHANNES , LONG STEPHEN K , VISSER GERBEN M , KRUSE CORNELIS G , VAN SCHARRENBURG GUSTAAF J M , TOOROP ANNE G HF , TOOROP GERRIT P
IPC: A61K31/40 , A61K31/4164 , A61K31/42 , A61K31/425 , A61K31/4439 , A61K31/496 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D209/34 , C07D235/26 , C07D263/58 , C07D277/68 , C07D401/04 , C07D413/04 , C07D417/04
Abstract: The invention relates to a group of novel piperazine and piperidine derivatives of formula (I), wherein: S1 is hydrogen, halogen, alkyl (1-3C), CN, CF3, OCF3, SCF3, alkoxy (1-3C), amino or mono- or dialkyl (1-3C) substituted amino, or hydroxy; X represents NR3, S, CH2, O, SO or SO2, wherein R3 is H or alkyl (1-3C); . . . Z represents =C or -N; -R1 independently represent H or alkyl (1-3C), or R1 and R2 together can form a bridge 2 or 3 C-atoms; R4 is hydrogen or alkyl (1-3C); Q is methyl, ethyl, ethyl substituted with one or more fluorine atoms, cyclopropyl-methyl, optionally substituted with one or more fluorine atoms, and salts and prodrugs thereof. It has been found that these compounds have both partial dopamine D2-receptor agonism and partial serotonin 5-HT1A-receptor agonism mediated activities.
-
公开(公告)号:DZ2934A1
公开(公告)日:2004-03-15
申请号:DZ990234
申请日:1999-11-10
Applicant: DUPHAR INT RES
Inventor: FEENSTRA ROELOF W , HEIJDEN VAN DER JOHANNES A M , MOS JOHANNES , LONG STEPHEN K , VISSER GERBEN M , KRUSE CORNELIS G , SCHARRENBURG GUSTAAF J M , TOOROP GERRIT P
IPC: A61K31/40 , A61K31/4164 , A61K31/42 , A61K31/425 , A61K31/4439 , A61K31/496 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D209/34 , C07D235/26 , C07D263/58 , C07D277/68 , C07D401/04 , C07D413/04 , C07D417/04 , C07D , A61K , A61P
Abstract: The invention relates to a group of novel piperazine and piperidine derivatives of formula (I), wherein: S1 is hydrogen, halogen, alkyl (1-3C), CN, CF3, OCF3, SCF3, alkoxy (1-3C), amino or mono- or dialkyl (1-3C) substituted amino, or hydroxy; X represents NR3, S, CH2, O, SO or SO2, wherein R3 is H or alkyl (1-3C); . . . Z represents =C or -N; -R1 independently represent H or alkyl (1-3C), or R1 and R2 together can form a bridge 2 or 3 C-atoms; R4 is hydrogen or alkyl (1-3C); Q is methyl, ethyl, ethyl substituted with one or more fluorine atoms, cyclopropyl-methyl, optionally substituted with one or more fluorine atoms, and salts and prodrugs thereof. It has been found that these compounds have both partial dopamine D2-receptor agonism and partial serotonin 5-HT1A-receptor agonism mediated activities.
-
公开(公告)号:HU0104922A2
公开(公告)日:2002-08-28
申请号:HU0104922
申请日:1999-11-10
Applicant: DUPHAR INT RES
Inventor: FEENSTRA ROELOF WILLEM , KRUSE CORNELIS G , LONG STEPHEN K , MOS JOHANNES , TOOROP GERRIT P , VISSER GERBEN M , VAN SCHARRENBURG GUSTAAF JOHAN , VAN DER HEIJDEN JOHANNES A M
IPC: A61K31/40 , A61K31/4164 , A61K31/42 , A61K31/425 , A61K31/4439 , A61K31/496 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D209/34 , C07D235/26 , C07D263/58 , C07D277/68 , C07D401/04 , C07D413/04 , C07D417/04
Abstract: The invention relates to a group of novel piperazine and piperidine derivatives of formula (I), wherein: S1 is hydrogen, halogen, alkyl (1-3C), CN, CF3, OCF3, SCF3, alkoxy (1-3C), amino or mono- or dialkyl (1-3C) substituted amino, or hydroxy; X represents NR3, S, CH2, O, SO or SO2, wherein R3 is H or alkyl (1-3C); . . . Z represents =C or -N; -R1 independently represent H or alkyl (1-3C), or R1 and R2 together can form a bridge 2 or 3 C-atoms; R4 is hydrogen or alkyl (1-3C); Q is methyl, ethyl, ethyl substituted with one or more fluorine atoms, cyclopropyl-methyl, optionally substituted with one or more fluorine atoms, and salts and prodrugs thereof. It has been found that these compounds have both partial dopamine D2-receptor agonism and partial serotonin 5-HT1A-receptor agonism mediated activities.
-
-
-
-
-
-
-
-
-